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Type 2 idiopathic macular telangiectasia (MacTel-2) is a progressive adult-onset macular disease associated with
bilateral perifoveal vascular changes, Muller cell degeneration and increased blood-retinal barrier permeability.
The pathophysiological mechanisms of MacTel-2 remain unclear, however it was previously reported that antiretinal antibodies in MacTel-2 patients are a significant feature of the disease. In this study, we aimed to compare
the prevalence of anti-retinal antibodies in patients MacTel-2, healthy controls and patients with other retinal
diseases. MacTel-2 patients diagnosed with multimodal imaging were enrolled and their disease severities were
graded using spectral-domain optical coherence tomography. For comparison, patients with age-related macular
degeneration (AMD), inherited retinal diseases (IRDs) or no retinal disease (healthy controls) were recruited as
controls. Blood serum samples were screened for immunoglobulin G anti-retinal antibodies by western blotting,
followed by densitometry analysis. Odds ratios (OR) with 95% confidence intervals (CI) were calculated and p <
0.05 considered statistically significant. Overall, anti-retinal antibody-positive cases were older (64 ± 15 vs 53
± 17 years, p < 0.001) and females were more likely to develop anti-retinal antibodies (OR: 2.41, CI: 1.12–5.18).
The frequency of anti-retinal antibody detection in MacTel-2 patients (n = 42, 36%) was not significantly
different from healthy controls (n = 52, 25%) or IRD patients (n = 18, 25%) and the majority of MacTel-2
patients had no anti-retinal antibodies. In contrast, the frequency of anti-retinal antibody detection was signif
icantly higher in patients with AMD (n = 15, 73%, p < 0.001). The lack of a greater anti-retinal antibody fre
quency or specificity in the MacTel-2 cohort suggests that antibody mediated immunological mechanisms may
play a less significant role in MacTel-2 disease pathogenesis.

Abbreviations: AMD, age-related macular degeneration; ARA, anti-retinal antibody; BRB, blood-retinal barrier; BCVA, best-corrected visual acuity; CI, confidence
interval; IRDs, inherited retinal diseases; MacTel-2, Type 2 idiopathic macular telangiectasia; OR, Odds ratio; SD, standard deviation; SD-OCT, spectral-domain
optical coherence tomography.
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1. Introduction

2.3. Study subjects

Type 2 idiopathic macular telangiectasia (MacTel-2) is a progressive
adult-onset macular disease associated with bilateral perifoveal vascular
changes, Muller cell degeneration and increased blood-retinal barrier
(BRB) permeability (Charbel Issa et al., 2013; Powner et al., 2010). The
breakdown of the BRB is also a feature of other, more common retinal
diseases including age-related macular degeneration (AMD) and
inherited retinal diseases (IRDs) (Adamus, 2015; Ahn et al., 2006;
Fishman et al., 1986). Impaired function of the BRB may release retinal
antigens to the systemic circulation, triggering non-specific autoimmune
antibody-antigen responses that may contribute to retinal disease
pathogenesis and progression (Vinores et al., 2001; Zhu et al., 2013).
An association between anti-retinal antibodies (ARAs) and MacTel-2
was previously reported by Zhu et al. (2013) in a cohort of 45 patients
(69%) compared to 58 healthy controls (16%). The three most prevalent
ARAs in MacTel-2 patients were found to bind the 40 kilo-Dalton (kDa)
creatine kinase type B (CK-B, 20%), the 120 kDa retinol-binding protein
3 (RBP3, 24%) and the 150 kDa glycogen debranching enzyme (AGL,
9%) (Zhu et al., 2013). Although each of these specific ARA were present
in less than a quarter of MacTel-2 patients tested, the detection of at least
one ARA in 69% of MacTel-2 patients raised the question of whether the
development of autoimmune responses directed against the retina could
play a role in the etiology of MacTel-2. Subsequent genetic and metab
olomic studies have implicated altered amino acid and lipid metabolism
as the more likely putative basis of photoreceptor damage in patients
with MacTel-2, and any definite role of ARAs in the pathogenesis of this
disease process has yet to be elucidated (Gantner et al., 2019).
This study aims to further clarify the clinical relevance of ARAs
associated with MacTel-2, by providing broader comparisons of the IgG
ARA profile with other non-MacTel-2 retinal disease entities that also
exhibit impaired BRB, as well as healthy controls. Furthermore, the re
lationships between ARA profile and MacTel-2 disease severity are
explored.

Patients with MacTel-2, age-related macular degeneration (AMD) or
inherited retinal diseases (IRDs) and subjects with no retinal disease
were recruited. The criteria for the MacTel-2 enrolment included a
clinical diagnosis of MacTel-2 supported by multimodal imaging and
with no signs of diabetic retinopathy or AMD. Severity of MacTel-2 was
graded by two retinal specialists independently (CB, FKC) on the basis of
colour fundus photographs, SD-OCT images, fundus autofluorescence
and fluorescein angiography (where available) and/or OCT angiog
raphy, using the staging system described by Chew et al. (2019) (Sup
plementary Table S1). The cohort was divided into early (grades 0-3)
and advanced stages (grades 4–7) for further analysis (Supplementary
Table S2). A control cohort consisted of patients with AMD and IRDs, We
used the Beckman classification for AMD cases as described by Ferris 3rd
et al. (Ophthalmology 2013; 120(4):844-51). Blood sampling in patients
with choroidal neovascularization were performed after stabilization of
the lesion with anti-vascular endothelial growth factor agents (Supple
mentary Table S3). IRD cases were diagnosed on a clinical basis by three
retinal specialists with subspecialty expertise on IRD (LAY and CB in
New York and CB and FKC in Perth), and confirmed by further multi
modal imaging, electrophysiology and genetic analysis through Molec
ular Vision Laboratory, Oregon, US, where available (Supplementary
Table S4). These non-MacTel-2 retinal diseases were selected given their
known association with BRB dysfunction. An additional cohort con
sisting of healthy control subjects without retinal disease (Supplemen
tary Table S5) were also included on basis of normal retinal examination
and multimodal imaging to provide a background ARA frequency and
profile. For all participants, age, sex and medical history were recorded.
2.4. Blood collection
Patient blood samples were collected in BD Vacutainer® Plus Plastic
Serum Tubes (Becton Dickinson and Company, Franklin Lakes, NJ, USA)
and allowed to clot at room temperature for 30–60 min. Blood samples
were centrifuged at 2000g for 15 min at 4 ◦ C to separate serum from red
blood cells. Serum was removed and stored at − 80 ◦ C prior to analysis.

2. Methods
2.1. Human participants

2.5. Retinal protein extraction

The study was conducted under the research protocol approved by
the Human Ethics Office of Research Enterprise, The University of
Western Australia (RA/4/1/7916) and the North Shore-Long Island
Jewish Health System (IRB#14–655), New York, USA. Collection and
use of human retinal tissue obtained from the Lions Eye Bank of Lions
Eye Institute was approved by the University of Western Australia
Human Research Ethics committee (RA/4/1/9327 and RA/4/20/5717).
Written informed consent was obtained from all participants who pro
vided serum samples. This research adhered to the tenets of the Decla
ration of Helsinki and was performed in accordance with the Health
Insurance Portability and Accountability Act regulations.

Whole retinal tissues (excluding retinal pigment epithelium) were
dissected from posterior eye cups obtained from human donors (aged
28–61) and lysed in RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO,
USA) with 1% Protein Inhibitor Cocktail (Sigma) followed by shaking at
4 ◦ C for 1 h. Lysates were then centrifuged at 15,700g for 30 min at 4 ◦ C
and the supernatant collected and stored at − 20 ◦ C. Protein concen
tration was determined by Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA, USA).
2.6. Anti-retinal antibody screening

2.2. Clinical phenotyping

For western blotting, human retinal protein was mixed with 4x
NuPAGE LDS Sample Buffer (Invitrogen, Thermo Fisher, Scientific,
Waltham MA, USA) and heated at 70 ◦ C for 10 min before loading into a
57 mm well spanning the NuPAGE 4–12% Bis-Tris gel (Invitrogen). A
total of 228 μg (4 μg/mm) of retinal protein was used on each blot.
Chameleon Duo Pre-stained Protein Ladder (LI-COR Biosciences,
Lincoln, Nebraska USA) was loaded into separate wells flanking the gel.
Proteins were separated by gel electrophoresis in MES buffer (Invi
trogen), and then transferred onto a PVDF membrane (Immobilon-FL,
Merck Millipore, Billerica, MA, USA) at 80V for 90 min in transfer buffer
(25 mM Tris, 190 mM glycine, 20% methanol, pH 8.3). After transfer,
the membrane was incubated with blocking buffer (5% BSA in TBS) at
room temperature for 1 h. Membranes were then loaded onto MiniPROTEAN® II Multiscreen Apparatus (Biorad) and incubated with pa
tient serum (1:200) or rabbit anti-RP1 antibody (1:1000, HPA042257,

Participants were recruited from the Vitreous, Retina Macula Con
sultants of New Year, New York, United States of America and the Lions
Eye Institute, Perth, Western Australia, Australia. All eligible subjects
underwent a complete ophthalmic assessment including best-corrected
visual acuity (BCVA), dilated slit lamp and fundus examination.
Detailed multi-modal imaging was performed, incorporating color
fundus photography (California, Optos plc., Dunfermline, UK), spectraldomain optical coherence tomography (SD-OCT, Spectralis, Heidelberg
Engineering, Heidelberg, Germany) and short-wave fundus auto
fluorescence (HRA2 or HRA+OCT, Heidelberg Engineering, Heidelberg,
Germany). Fluorescein angiography or OCT angiography (RTVue XR
Avanti system, Optovue, Inc, CA, USA) were performed to confirm the
vascular changes in MacTel-2.
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Sigma) diluted in blocking buffer at 4 ◦ C overnight. Blots were then
washed in TBST 3 times and the membrane incubated with IRDye®
800CW Goat anti-Human IgG (1:10,000; LI-COR) secondary antibodies
diluted in 5% BSA in TBST for 1 h at room temperature. IRDye® 800CW
Goat anti-Rabbit IgG (1:10,000; LI-COR) secondary antibody was used
for anti-RP1 blotting. The membrane was washed then 3 times in TBST,
and once with TBS without Tween20. The membrane was imaged at 800
nm wavelength using the Odyssey Infrared Imager (Model 9120, LICOR).
Western blots included lanes probed with positive control serum
from a single patient with paraneoplastic retinopathy associated with a
high-grade small cell neuroendocrine tumour in the prostate (Chen
et al., 2017). Additionally, to provide a reproducible reference band for
retinal protein western blots we included lanes probed with a com
mercial antibody targeting RP1, a retinal protein expressed in photo
receptors. Labelling of bands in the RP1 positive control lane was used as
a reference to standardise imaging intensities between different blots.
Densitometry profiles were generated for each lane using the Image J64
software (version 1.44◦ , National Institutes of Health, USA). Distance
migrated and labelling intensities were measured for each band. Band
intensities were normalized against the labelling of the 200 kDa RP1
antigen. Band intensities greater than 50% of the RP1 control band were
scored positive. Protein marker size was plotted against distance
migrated to generate standard curves for determination of antigen sizes.
Using this method, protein sizes could be determined from 8 to 260 kDa.
To measure the errors associated with band size measurement, we
compared size measurements for the 100 kDa band and 45 kDa bands
labeled by an AIR patient used as a positive control across 21 western
blots. Errors associated with size measurements were lower for the
smaller band (SD = 1.04 kDa), than the larger band (SD = 6.36 kDa)
(Supplementary Fig. S1).

Table 1
Patient demographics.
Group

n

Female:
Male

Mean age (range,
years)

MacTel-2
Early
Advanced
Healthy Control (no retinal
disease)
Retinal disease
AMD
IRDs
Whole group

42
18
24
52

29:13
12:6
17:7
23:29

62 (38–88)
64 (38–77)
62 (39–88)
50 (23–75)

35
15
20
129

18:17
8:7
10:10
70:59

59 (11–99)
79 (58–99)
44 (11–80)
62 (11–99)

AMD, age-related macular degeneration; IRDs, inherited retinal diseases;
MacTel-2, type 2 macular telangiectasia.

46%) than those in the healthy control group (25%, χ2 (1, N = 87) =
4.039, p = 0.04, Fig. 1B). A subgroup analysis showed that only AMD
patients, but not IRDs patients, early MacTel-2 or advanced MacTel-2
cohorts had a higher frequency of ARA compared to those in the
healthy control group (χ2 (1, N = 67) = 11.83, p = 0.0006) (Fig. 1B).
Reducing the cut off thresholds from 50% to 33% of control band in
tensity values for positive ARA-calling led to an increase in ARA fre
quency across all groups, while the relationships between groups
remained unchanged (Supplementary Fig. S2). We further applied a
logistic regression model to determine if ARA band intensity is a
discriminator of the groups, after adjusting for gender and age. Using
this model, the presence of ARA remained a significant discriminator for
AMD patients (p = 0.02) but not for Mactel-2 or IRD patients (p > 0.05,
Table 2), compared with healthy controls.
3.3. Demographic features of anti-retinal antibody positive cases

2.7. Statistical analysis

Overall, ARA positive cases were significantly older than ARA
negative cases (64 ± 15 vs 53 ± 17 years, p < 0.001). For the MacTel-2
and healthy retina groups, there were no significant differences in the
mean age between ARA positive and negative cases (Table 3). However,
in the non-MacTel-2 retinal disease group, age was significantly higher
in ARA positive compared to ARA negative cases (71 ± 18 years vs 49 ±
24 years, p = 0.004, Table 3). Overall, IgG ARAs were more frequently
detected in female (43%) than in male individuals (24%, χ2 (1, N = 129)
= 5.212, p = 0.02, Supplementary Fig. S3). Conversely, there were more
females in ARA positive cases than in ARA negative cases (68% vs 47%).
Females were more likely than males to develop IgG ARA (odds ratio
[OR] 2.41 [95% Confidence interval [CI, 1.12–5.18]). This association
was driven by the healthy control group, with 39% of healthy female
subjects showing ARA positivity, compared with 14% of healthy male
controls ([OR] 4.02 [CI, 1.04–15.46], Supplementary Fig. S3). The fe
male:male odds ratios of IgG ARA (95% CI) for the MacTel-2 and retinal
disease groups were only 2.35 (0.53–10.41) and 1.43 (0.38–5.44),
respectively.

Proportion, mean and standard deviation (SD) were calculated. Chisquare and independent sample t-tests were used to compare the pro
portions of ARA positive cases between the cohorts and the mean age of
ARA positive versus negative cases. Odds ratios (OR) with 95% confi
dence intervals (CI) of females developing ARA were calculated. A pvalue of <0.05 was considered statistically significant. Linear regression
analysis was performed using Excel (Microsoft, USA).
3. Results
3.1. Patient demographics and diagnosis
A total of 129 blood samples were collected from 42 patients with
MacTel-2, 35 patients with non-Mactel-2 retinal disease (AMD; n = 15
and IRDs; n = 20) and 52 subjects with no retinal disease (healthy
controls). The mean (SD) ages for MacTel-2 and non-MacTel-2 retinal
disease groups; 62.4 (11.1), 59.1 (23.9) were significantly greater than
the healthy controls; 50.2 (13.6) years (p < 0.001 and p = 0.03,
respectively, Table 1). Seventy percent of the MacTel-2 cohort was fe
male, compared with 51% and 42% of the cohorts with non-Mactel-2
retinal disease and healthy controls respectively (χ2 (2, N = 129) =
5.92, p = 0.05, Table 1). There was no relationship between disease
stage and age in the MacTel-2 cohort (Fig. 1A). The MacTel-2 grading
scale and the clinical and genetic diagnoses for the cohort with retinal
disease are provided in Supplementary Tables S2, S3 and S4.

3.4. Anti-retinal antibody profile
The sizes of retinal antigens labeled by IgG ARA varied considerably,
with most patients displaying a unique pattern of immunoreactivity. To
identify potential disease specific antigen profiles, we plotted the fre
quencies of ARA-labeled bands against antigen size for the healthy
control cohort (n = 13 ARA positive patients), the MacTel-2 cohort (n =
15) and the AMD group (n = 11) (Fig. 1B). In the healthy control group,
the most commonly detected antigens were a 34–36 kDa antigen, a
39–41 kDa antigen and a 45–47 kDa antigen in 31%, 23% and 23% of
the ARA positive subjects, respectively. In the MacTel-2 group, the most
common antigens detected were 45–47 kDa and 75–79 kDa in size;
present in 27% of ARA positive cases for both. In the AMD group, the
most commonly detected antigens were 45–47 kDa and 48–50 kDa in

3.2. Anti-retinal antibody frequency in the three disease groups
There were no significant differences between the frequencies of
positive IgG ARA in subjects with MacTel-2 (36%) and healthy controls
(25%, χ2 (1, N = 94) = 1.275, p = 0.26). However, the frequency of ARA
was higher in the non-MacTel-2 retinal disease cohort (AMD or IRDs,
3
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Fig. 1. A) Patients in the MacTel-2 cohort were plotted by age and MacTel grade. Linear regression analysis demonstrated no correlation between patient age and
disease severity (dotted line, R = 0.00047). B) ARA frequencies were calculated for each group using a cut off threshold of 50% of the 200 kDa anti-RP1 control band.
No significant differences in the frequency of ARA detection were found between healthy controls and patients with MacTel-2 (early, advanced or total) or patients
with other retinal diseases or IRDs. In contrast, the AMD patient subgroup showed significantly increased rates of ARA detection (p < 0.0001). C) ARA-binding
antigens detected were binned according to size and plotted against their frequencies in ARA-positive healthy controls, MacTel-2 patients and AMD patients.
Table 2
Logistic regression model estimates with healthy controls as the reference
outcome level.
Predictor

Model Estimate

AMD vs Healthy
Intercept
− 26.2 (− 53.4,-12.3)
%RP1
4.1 (1.4,8.7)
Genderb
2.0 (− 0.6,5.5)
Age in years
0.3 (0.1,0.7)
IRD vs Healthy
Intercept
0.9 (− 1.3,3.1)
%RP1
1.3 (− 0.6,3.3)
b
Gender
− 0.5 (− 1.7,0.6)
Age in years
− 0.044 (− 0.09,-0.004)
Mactel-2 vs Healthy
Intercept
− 4.7 (− 7.6,-2.3)
%RP1
1.4 (− 0.1,3.2)
Genderb
− 0.4 (− 1.4,0.6)
Age in years
0.1 (0,0.1)
a
b

OR (95% CI)

p-Value

0.0 (0.0,0.0)
60.2 (4.1,5774.2)
7.1 (0.6,239.5)
1.4 (1.2,2)

0.018a
0.178
0.013a

2.4 (0.3,22.8)
3.8 (0.5,27)
0.6 (0.2,1.9)
0.957 (0.914,0.996)

0.170
0.380
0.041a

0.0 (0.0,0.1)
4 (0.9,23.7)
0.7 (0.2,1.8)
1.1 (1,1.1)

0.094
0.422
0.001a

Table 3
Mean age of anti-retinal antibody positive versus negative cases.
Group

Mean Age in those
without ARA (±SD)

Mean Age in
those with ARA
(±SD)

Mean age
(All, ±SD)

MacTel-2a
Earlya
Advanceda
Healthy Controla(no
retinal disease)
Retinal diseaseb
AMDa
IRDsa
Whole groupc

62 ± 11
67
60
49 ± 14

63 ± 11
60
66
55 ± 12

62
64
62
50

49 ± 24
80
41
53 ± 17

71 ± 18
79
54
64 ± 15

59
79
44
62

ARA, anti-retinal antibody; AMD, age-related macular degeneration; IRDs,
inherited retinal diseases; MacTel-2, type 2 macular telangiectasia.
a
No statistically significant difference in age.
b
Difference in age was statistically significant, p = 0.004.
c
Difference in age was statistically significant, p = 0.0007.

Significant at 5% level.
Female = reference category; OR = odds ratio, CI = confidence interval.

rate in their MacTel-2 cohort is likely to be related to methodological
differences in ARA assay as their methodology did not discriminate
between IgG, IgA or IgM isotypes. Polyreactive IgM autoantibodies that
bind to self-antigens with moderate affinities and high avidities are
known to occur in healthy individuals (Elkon and Casali, 2008). These
IgM antibodies recognize a broad spectrum of microbial targets and play
an important role in defending against invading pathogens. Addition
ally, recognition of self-antigens by autoantibodies contributes to the
development and homeostasis of the immune system. IgM antibodies

size, present in 36% of ARA positive cases for both.
4. Discussion
In this study, we demonstrated no significant increase in frequency of
IgG ARA amongst patients with MacTel-2 compared to healthy control
subjects. Previously, Zhu et al. (2013) detected ARA in 69% of MacTel-2
patients, compared with 16% of healthy control subjects. The higher
4

S. McLenachan et al.

Experimental Eye Research 218 (2022) 109024

may bind to multiple unrelated antigens and are present in healthy in
dividuals, while high-affinity IgG autoantibodies are generally thought
to reflect a pathological autoimmune response (Elkon and Casali, 2008)
and for this reason we focused our ARA screening on IgG detection only.
IgG ARA were previously detected in 58% (64/108) of patients with
AMD compared to 54% (14/26) of healthy controls (Adamus et al.,
2014). The higher rate reported in this healthy control cohort may be
related to differences in the cut off threshold used for band-calling. In
our study, a quantitative, densitometry-based method was used for ARA
detection in patient serum samples by western blotting. Labeling in
tensity was standardized by including a lane probed with anti-RP1
antibody in all blots, enabling normalization of signals between blots.
Additionally, a positive control sample from an ARA positive patient
with paraneoplastic autoimmune retinopathy was included on every
blot. These controls were used to determine cut off thresholds for band
positivity, which were set at 50% of the RP1 positive control band.
Reducing the threshold to 33% of the RP1 reference band increased the
number of positive patients detected by approximately 20% in all groups
except the AMD group, which increased by 7%. Since this increase in
ARA frequency occurred evenly across the MacTel-2, healthy control
and the IRDs groups without affecting the AMD group, it is likely that it
reflects an increase in detection of false positive bands. The significance
of these low intensity bands remains uncertain, however their relative
abundance in the healthy population suggests they are not pathogenic in
nature.
ARA detection rates were high in AMD patients (73%), supporting
previous studies indicating the development of IgG ARA is a significant
feature of AMD (Adamus et al., 2014; Chen et al., 1993; Cherepanoff
et al., 2006; Iannaccone et al., 2015; Kubicka-Trząska et al., 2014;
Morohoshi et al., 2012; Patel et al., 2005). Adamus et al. (2014) showed
that increases in IgG ARA detection rates were only significant in AMD
patients with less severe disease phenotypes, suggesting IgG ARA may be
a biomarker or indeed play a role in early stage disease. Although we
were unable to compare AMD subgroups due to low patient numbers in
the group, we observed a similar trend in the MacTel-2 cohort.
In contrast with the AMD group, the IRD group showed no significant
difference in ARA frequency compared with healthy controls. ARA have
previously been detected in animal models of IRDs (Adamus et al., 2012;
Iannaccone and Radic, 2019; Kyger et al., 2013) as well as human pa
tients with retinitis pigmentosa (Chant et al., 1985; Heckenlively et al.,
1985, 1999, 2000). In early studies, Chant et al. reported ARA fre
quencies of up to 37% in retinitis pigmentosa (RP) patients (Chant et al.,
1985), while later studies showed ARA were detected in up to 90% of RP
patients with cystoid macular oedema (CMO), but only 13% of RP pa
tients without CMO (Heckenlively et al., 1999). In our study, only 3/20
IRD patients had CMO and all of them were negative for IgG ARA. These
ARA negative cases may reflect the young age of one CMO patient (14yo
with MERTK mutations) or the mild disease in the other CMO patients
(29yo with RHO mutation and 34yo with USH2A mutation).
Overall, the MacTel-2 group did not show a significant increase in
IgG ARA detection rates compared with healthy controls (36% vs 25%).
However, when early and advanced stage disease subgroups were ana
lysed separately, the presence of IgG ARA was further increased in pa
tients with early stage disease (44%) while ARA detection rates in
patients with advanced stage MacTel-2 (29%) were similar to healthy
controls (25%). In support of an association between ARA positivity and
early stage MacTel-2, the mean age of the ARA positive patients was
lower than the mean age of the ARA negative cases. In contrast, the ARA
positive healthy control cohort and IRDs subgroup were older than those
without ARA, while ARA positive and negative AMD groups were of
similar ages (Table 3). However, since these differences did not achieve
statistical significance, the clinical significance of ARA in early stage
MacTel-2 warrants further investigation.
Antigen profiles were found to be highly variable between ARA
positive Mactel-2 patients. Zhu et al. (2013) found three commonly
labeled antigens (AGL, RBP3 and CK-B) using mass spectrometry. In the

present study, we found no evidence for increased frequencies of CK-B
(40 kDa), RBP3 (120 kDa) or AGL (150 kDa) reactive IgG ARAs in
MacTel-2 patients. Reactivity to a 39–41 kDa antigen was observed in
only 1/42 MacTel-2 patients, but was found in 3/52 subjects in the
healthy control group. No IgG ARA-positive antigens were found to have
molecular weights of 120 kDa or 150 kDa, although 2 MacTel-2 patients
showed reactivity to a 190 kDa band. Within the MacTel-2 group, the
most common antigens detected were 45–47 kDa and 75–79 kDa in size,
which each occurred in only four out of 42 MacTel-2 patients. Reactivity
to a 45–47 kDa antigen was detected in >20% of ARA positive cases in
all groups, with the highest detection rates found in the AMD group
(35%). Previously, Adamus et al. identified a 46 kDa antigen as the most
commonly detected ARA target in both control subjects and in patients
with AMD (Adamus et al., 2014). The authors proposed this antigen was
enolase based on its size.
In our study, high intensity signals (>50% of the RP1 reference band)
were present in only 25% of healthy controls. It is possible that the
strong IgG ARA signals in these control subjects represent polyreactivity
of antibodies directed at other antigens, which bind to retinal proteins
on western blots as an off-target effect or due to epitope unmasking
during protein denaturation. On the other hand, in some control sub
jects, development of ARA may reflect smoking status (Adamus et al.,
2014) or the presence of undiagnosed cancers (Adamus, 2009; Chen
et al., 2017).
Female patients were more likely to present with ARA reactivities
than male patients across all groups, consistent with known differences
in humoral immunity between the sexes (Klein and Flanagan, 2016).
Females have higher circulating immunoglobulin levels than men, as
well as an increased incidence of autoimmune disease (Fink and Klein,
2018; Wilhelmson et al., 2018).
5. Study limitations
A general limitation of ARA detection by western blot is the relative
abundance of specific retinal proteins presenting on the blot. Binding of
ARA to low abundance retinal antigens may not produce sufficient
signal for discrimination from non-specific background signals evident
in densitometry traces. Future studies investigating ARA reactivities to
specific retinal antigens may help to overcome this limitation. The
unique retinal antigen profile in patients with MacTel-2 has not been
fully characterised yet and this is an opportunity for a future study. An
additional limitation is that this study utilized neuroretinal tissues as a
source of retinal antigens. Further studies utilizing retinal pigment
epithelium as the antigen source could be performed to investigate the
potential role of anti-RPE antibodies in MacTel-2. Finally, eight of the
twenty patients with IRDs did not have a confirmed causative mutation
due to lack of testing or inconclusive results. Therefore, differences in
ARA frequency may be confounded by misdiagnosis of non-hereditary
phenocopies as IRDs.
6. Conclusions
In summary, we found the majority of MacTel-2 patients tested
negative for IgG ARA and the frequency of ARA was only marginally
greater than healthy controls. The finding of a trend towards higher
frequency of ARA in those with early MacTel-2 may warrant further
investigation, however the lack of a strong association with greater ARA
frequency or specificity in the MacTel-2 cohort suggests that antibody
mediated immunological mechanisms are unlikely to play a significant
role in disease pathogenesis.
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